The GH/IGF-1 axis in obesity: Pathophysiology and therapeutic considerations

Nature Reviews Endocrinology

Volumn 9, Issue 6, 2013, Pages 346-356

  Berryman, Darlene E ^a   Glad, Camilla A M ^b   List, Edward O ^a   Johannsson, Gudmundur ^b  

^a OHIO UNIVERSITY   (United States)

^b SAHLGRENSKA UNIVERSITY HOSPITAL   (Sweden)

Author keywords

[No Author keywords available]

Indexed keywords

ADIPONECTIN; GLUCOSE; GROWTH HORMONE; GROWTH HORMONE RECEPTOR; LEPTIN; LIPID; MESSENGER RNA; PIOGLITAZONE; PLACEBO; SOMATOMEDIN C;

ABDOMINAL FAT; ADIPOCYTE; BROWN ADIPOSE TISSUE; CELL INFILTRATION; GENETIC POLYMORPHISM; GLUCOSE METABOLISM; GROWTH HORMONE RELEASE; GROWTH HORMONE SECRETING CELL; HUMAN; IMMUNOCOMPETENT CELL; INSULIN SENSITIVITY; INTRAABDOMINAL FAT; LIPID METABOLISM; NONHUMAN; OBESITY; PRIORITY JOURNAL; PROTEIN EXPRESSION; REVIEW; SIGNAL TRANSDUCTION; WHITE ADIPOSE TISSUE;

ADIPOSE TISSUE; BODY COMPOSITION; HUMAN GROWTH HORMONE; HUMANS; INSULIN-LIKE GROWTH FACTOR I; OBESITY;

EID: 84879117813     PISSN: 17595029     EISSN: 17595037     Source Type: Journal    
DOI: 10.1038/nrendo.2013.64     Document Type: Review

References (146)

1. Møller, N. & Jørgensen, J. O. Effects of growth hormone on glucose, lipid, and protein metabolism in human subjects. Endocr. Rev. 30, 152-177 (2009).
2. Rabinowitz, D., Klassen, G. A. & Zierler, K. L. Effects of human growth hormone on muscle and adipose tissue metabolism in the forearm of man. J. Clin. Invest. 44, 51-61 (1965).
3. Bray, G. A. Calorigenic effect of human growth hormone in obesity. J. Clin. Endocrinol. Metab. 29, 119-122 (1969).
4. Bengtsson, B. A. et al. Treatment of adults with growth hormone (GH) deficiency with recombinant human GH. J. Clin. Endocrinol. Metab. 76, 309-317 (1993).
5. Angelin, B. & Rudling, M. Growth hormone and hepatic lipoprotein metabolism. Curr. Opin. Lipidol. 5, 160-165 (1994).
6. Saccà, L., Cittadini, A. & Fazio, S. Growth hormone and the heart. Endocr. Rev. 15, 555-573 (1994).
7. Böger, R. H. et al. Nitric oxide may mediate the hemodynamic effects of recombinant growth hormone in patients with acquired growth hormone deficiency. J. Clin. Invest. 98, 2706-2713 (1996).
8. [No authors listed] Consensus guidelines for the diagnosis and treatment of adults with growth hormone deficiency: summary statement of the Growth Hormone Research Society Workshop on Adult Growth Hormone Deficiency. J. Clin. Endocrinol. Metab. 83, 379-381 (1998).
9. Johannsson, G. Management of adult growth hormone deficiency. Endocrinol. Metab. Clin. North Am. 36, 203-220 (2007).
10. Maison, P. et al. Impact of growth hormone (GH) treatment on cardiovascular risk factors in GH-deficient adults: a meta-analysis of blinded, randomized, placebo-controlled trials. J. Clin. Endocrinol. Metab. 89, 2192-2199 (2004).
11. Clasey, J. L. et al. Abdominal visceral fat and fasting insulin are important predictors of 24-hour GH release independent of age, gender, and other physiological factors. J. Clin. Endocrinol. Metab. 86, 3845-3852 (2001).
12. Vahl, N. et al. Abdominal adiposity rather than age and sex predicts mass and regularity of GH secretion in healthy adults. Am. J. Physiol. 272, E1108-E1116 (1997).
13. Vahl, N., Møller, N., Lauritzen, T., Christiansen, J. S. & Jørgensen, J. O. Metabolic effects and pharmacokinetics of a growth hormone pulse in healthy adults: relation to age, sex, and body composition. J. Clin. Endocrinol. Metab. 82, 3612-3618 (1997).
14. Lu, C., Kumar, P. A., Fan, Y., Sperling, M. A. & Menon, R. K. A novel effect of growth hormone on macrophage modulates macrophage-dependent adipocyte differentiation. Endocrinology 151, 2189-2199 (2010).
15. Fleenor, D., Arumugam, R. & Freemark, M. Growth hormone and prolactin receptors in adipogenesis: STAT-5 activation, suppressors of cytokine signaling, and regulation of insulin-like growth factor I. Horm. Res. 66, 101-110 (2006).
16. Lyuh, E. et al. Dose-specific or dose-dependent effect of growth hormone treatment on the proliferation and differentiation of cultured neuronal cells. Growth Horm. IGF Res. 17, 315-322 (2007).
17. Hattori, N. Expression, regulation and biological actions of growth hormone (GH) and ghrelin in the immune system. Growth Horm. IGF Res. 19, 187-197 (2009).
18. Fisker, S. et al. Gene expression of the GH receptor in subcutaneous and intraabdominal fat in healthy females: relationship to GH-binding protein. Eur. J. Endocrinol. 150, 773-777 (2004).
19. Fisker, S. et al. Gene expression of a truncated and the full-length growth hormone (GH) receptor in subcutaneous fat and skeletal muscle in GH-deficient adults: impact of GH treatment. J. Clin. Endocrinol. Metab. 86, 792-796 (2001).
20. Richelsen, B. et al. Growth hormone treatment of obese women for 5 wk: effect on body composition and adipose tissue LPL activity. Am. J. Physiol. 266, E211-E216 (1994).
21. Nam, S. Y. & Lobie, P. E. The mechanism of effect of growth hormone on preadipocyte and adipocyte function. Obes Rev. 1, 73-86 (2000).
22. Garten, A., Schuster, S. & Kiess, W. The insulin-like growth factors in adipogenesis and obesity. Endocrinol. Metab. Clin. North Am. 41, 283-295, v-vi (2012).
23. Cartwright, M. J. et al. Aging, depot origin, and preadipocyte gene expression. J. Gerontol. A. Biol. Sci. Med. Sci. 65, 242-251 (2010).
24. Tchkonia, T. et al. Identification of depot-specific human fat cell progenitors through distinct expression profiles and developmental gene patterns. Am. J. Physiol. Endocrinol. Metab. 292, E298-E307 (2007).
25. Blüher, M. Clinical relevance of adipokines. Diabetes Metab. J. 36, 317-327 (2012).
26. Childs, G. V. et al. The somatotrope as a metabolic sensor: deletion of leptin receptors causes obesity. Endocrinology 152, 69-81 (2011).
27. Sharp, L. Z. et al. Human BAT possesses molecular signatures that resemble beige/brite cells. PLoS ONE 7, e49452 (2012).
28. Lin, L. et al. Ablation of ghrelin receptor reduces adiposity and improves insulin sensitivity during aging by regulating fat metabolism in white and brown adipose tissues. Aging Cell 10, 996-1010 (2011).
29. Divoux, A. & Clément, K. Architecture and the extracellular matrix: the still unappreciated components of the adipose tissue. Obes. Rev. 12, e494-e503 (2011).
30. Vidal, H. Gene expression in visceral and subcutaneous adipose tissues. Ann. Med. 33, 547-555 (2001).
31. Lee, M. J., Wu, Y. & Fried, S. K. Adipose tissue heterogeneity: Implication of depot differences in adipose tissue for obesity complications. Mol. Aspects Med. 34, 1-11 (2013).
32. Sun, K., Kusminski, C. M. & Scherer, P. E. Adipose tissue remodeling and obesity. J. Clin. Invest. 121, 2094-2101 (2011).
33. Berryman, D. E. et al. Growth hormone and adipose tissue: beyond the adipocyte. Growth Horm. IGF Res. 21, 113-123 (2011).
34. Erman, A., Veilleux, A., Tchernof, A. & Goodyer, C. G. Human growth hormone receptor (GHR) expression in obesity: I. GHR mRNA expression in omental and subcutaneous adipose tissues of obese women. Int. J. Obes. (Lond.) 35, 1511-1519 (2011).
35. Giustina, A. & Veldhuis, J. D. Pathophysiology of the neororegulation of growth hormone secretion in experimental animals and the human. Endocr. Rev. 19, 717-797 (1998).
36. Iranmanesh, A., Lizarralde, G. & Veldhuis, J. D. Age and relative adiposity are specific negative determinants of the frequency and amplitude of growth hormone (GH) secretory bursts and the half-life of endogenous GH in healthy men. J. Clin. Endocrinol. Metab. 73, 1081-1088 (1991).
37. Veldhuis, J. D. et al. Dual effects in pulsatile growth hormone secretion and clearance subserve the hyposomatotropism of obesity in man. J. Clin. Endocrinol. Metab. 72, 51-59 (1991).
38. Williams, T. et al. Impaired growth hormone responses to growth hormone-releasing factor in obesity. A pituitary defect reversed with weight reduction. N. Engl. J. Med. 311, 1403-1407 (1984).
39. Vahl, N., Jørgensen, J. O., Jurik, A. G. & Christiansen, J. S. Abdominal adiposity and physical fittness are major determinants of age associated decline in stimulated GH secretion in healthy adults. J. Clin. Endocrinol. Metab. 81, 2209-2215 (1996).
40. Bredella, M. A. et al. Peak growth hormone-releasing hormone-arginine- stimulated growth hormone is inversely associated with intramyocellular and intrahepatic lipid content in premenopausal women with obesity. J. Clin. Endocrinol. Metab. 94, 3995-4002 (2009).
41. Franco, C. et al. Thigh intermuscular fat is inversely associated with spontaneous GH release in post-menopausal women with abdominal obesity. Eur. J. Endocrinol. 155, 261-268 (2006).
42. Vahl, N., Klausen, I., Christiansen, J. S. & Jorgensen, J. O. Growth hormone (GH) status is an independent determinant of serum levels of cholesterol and triglycerides in healthy adults. Clin. Endocrinol. (Oxf.) 51, 309-316 (1999).
43. Weltman, A. et al. Impact of abdominal visceral fat, growth hormone, fitness, and insulin on lipids and lipoproteins in older adults. Metabolism 52, 73-80 (2003).
44. Miller, K. K. et al. Truncal adiposity, relative growth hormone deficiency, and cardiovascular risk. J. Clin. Endocrinol. Metab. 90, 768-774 (2005).
45. Utz, A. L., Yamamoto, A., Hemphill, L. & Miller, K. K. Growth hormone deficiency by growth hormone releasing hormone-arginine testing criteria predicts increased cardiovascular risk markers in normal young overweight and obese women. J. Clin. Endocrinol. Metab. 93, 2507-2514 (2008).
46. Makimura, H., Stanley, T., Mun, D., You, S. M. & Grinspoon, S. The effects of central adiposity on growth hormone (GH) response to GH-releasing hormone-arginine stimulation testing in men. J. Clin. Endocrinol. Metab. 93, 4254-4260 (2008).
47. Buijs, M. M. et al. Blunted lipolytic response to fasting in abdominally obese women: evidence for involvement of hyposomatotropism. Am. J. Clin. Nutr. 77, 544-550 (2003).
48. Goodyer, C. G. et al. Organization and evolution of the human growth hormone receptor gene 5'-flanking region. Endocrinology 142, 1923-1934 (2001).
49. Godowski, P. J. et al. Characterization of the human growth hormone receptor gene and demonstration of a partial gene deletion in two patients with Laron-type dwarfism. Proc. Natl Acad. Sci. USA 86, 8083-8087 (1989).
50. Dos Santos, C. et al. A common polymorphism of the growth hormone receptor is associated with increased responsiveness to growth hormone. Nat. Genet. 36, 720-724 (2004).
51. Strawbridge, R. J. et al. GHR exon 3 polymorphism: association with type 2 diabetes mellitus and metabolic disorder. Growth Horm. IGF Res. 17, 392-398 (2007).
52. Gao, L. et al. The growth hormone receptor (GHR) exon 3 polymorphism and its correlation with metabolic profiles in obese Chinese children. Pediatr. Diabetes 12, 429-434 (2011).
53. Bray, G. A., Raben, M. S., Londono, J. & Gallagher, T. F. Jr. Effects of triiodothyronine, growth hormone and anabolic steroids on nitrogen excretion and oxygen consumption of obese patients. J. Clin. Endocrinol. Metab. 33, 293-300 (1971).
54. Clemmons, D. R., Snyder, D. K., Williams, R. & Underwood, L. E. Growth hormone administration conserves lean body mass during dietary restriction in obese subjects. J. Clin. Endocrinol. Metab. 64, 878-883 (1987).
55. Snyder, D. K., Clemmons, D. R. & Underwood, L. E. Treatment of obese, diet-restricted subjects with growth hormone for 11 weeks: effects on anabolism, lipolysis and body composition. J. Clin. Endocrinol. Metab. 67, 54-61 (1988).
56. Snyder, D. K., Underwood, L. E. & Clemmons, D. R. Anabolic effects of growth hormone in obese diet-restricted subjects are dose dependent. Am. J. Clin. Nutr. 52, 431-437 (1990).
57. Kim, K. R. et al. Low-dose growth hormone treatment with diet restriction accelerates body fat loss, exerts anabolic effect and improves growth hormone secretory dysfunction in obese adults. Horm. Res. 51, 78-84 (1999).
58. Tagliaferri, M. et al. Metabolic effects of biosynthetic growth hormone treatment in severely energy-restricted obese women. Int. J. Obes. Relat. Metab. Disord. 22, 836-841 (1998).
59. Fowelin, J., Attvall, S., Lager, I. & Bengtsson, B. A. Effects of treatment with recombinant human growth hormone on insulin sensitivity and glucose metabolism in adults with growth hormone deficiency. Metabolism 42, 1443-1447 (1993).
60. Jørgensen, J. O. et al. Fuel metabolism, energy expenditure, and thyroid function in growth hormone-treated obese women: a double-blind placebo-controlled study. Metabolism 43, 872-877 (1994).
61. Karlsson, C. et al. Effects of growth hormone treatment on the leptin system: interactions with body composition and energy expenditure. Eur. J. Endocrinol. 138, 408-414 (1998).
62. Jørgensen, J. O. et al. Effects of growth hormone therapy on thyroid function of growth hormone-deficient adults with and without concomittant thyroxine-substituted central hypothyroidism. J. Clin. Endocrinol. Metab. 69, 1127-1132 (1989).
63. Lapidus, L. et al. Distribution of adipose tissue and risk of cardiovascular disease and death: a 12 year follow up of participants in the population study of women in Gothenburg, Sweden. Br. Med. J. (Clin. Res. Ed.) 289, 1257-1261 (1984).
64. Larsson, B. et al. Abdominal tissue distribution, obesity and risk of cardiovascular disease and death: 13 year follow-up of participants in the study of men born in 1913. Br. Med. J. (Clin. Res. Ed.) 288, 1401-1404 (1984).
65. Johannsson, G. et al. Growth hormone treatment of abdominally obese men reduces abdominal fat mass, improves glucose and lipoprotein metabolism, and reduces diastolic blood pressure. J. Clin. Endocrinol. Metab. 82, 727-734 (1997).
66. Franco, C. et al. Growth hormone treatment reduces abdominal visceral fat in postmenopausal women with abdominal obesity: a 12-month placebo-controlled trial. J. Clin. Endocrinol. Metab. 90, 1466-1474 (2005).
67. Franco, C. et al. Growth hormone reduces inflammation in postmenopausal women with abdominal obesity: a 12-month, randomized, placebo-controlled trial. J. Clin. Endocrinol. Metab. 92, 2644-2647 (2007).
68. Lo, J. et al. Low-dose physiological growth hormone in patients with HIV and abdominal fat accumulation: a randomized controlled trial. JAMA 300, 509-519 (2008).
69. Clemmons, D. R. Roles of insulin-like growth factor-I and growth hormone in mediating insulin resistance in acromegaly. Pituitary 5, 181-183 (2002).
70. Jessen, N. et al. Evidence against a role for insulin-signaling proteins PI 3-kinase and Akt in insulin resistance in human skeletal muscle induced by short-term GH infusion. Am. J. Physiol. Endocrinol. Metab. 288, E194-E199 (2005).
71. Nielsen, C. et al. Growth hormone signaling in vivo in human muscle and adipose tissue: impact of insulin, substrate background, and growth hormone receptor bckade. J. Clin. Endocrinol. Metab. 93, 2842-2850 (2008).
72. Yakar, S. et al. Inhibition of growth hormone action improves insulin sensitivity in liver IGF-1-deficient mice. J. Clin. Invest. 113, 96-105 (2004).
73. Barbour, L. A. et al. Increased P85α is a potent negative regulator of skeletal muscle insulin signaling and induces in vivo insulin resistance associated with growth hormone excess. J. Biol. Chem. 280, 37489-37494 (2005).
74. del Rincon, J. P. et al. Growth hormone regulation of p85α expression and phosphoinositide 3-kinase activity in adipose tissue: mechanism for growth hormone-mediated insulin resistance. Diabetes 56, 1638-1646 (2007).
75. Bramnert M. et al. Growth hormone replacement therapy induces insulin resistance by activating the glucose-fatty acid cycle. J. Clin. Endocrinol. Metab. 88, 1455-1463 (2003).
76. Nam, S. Y. et al. Low-dose growth hormone treatment combined with diet restriction decreases insulin resistance by reducing visceral fat and increasing muscle mass in obese type 2 diabetic patients. Int. J. Obes. Relat. Metab. Disord. 25, 1101-1107 (2001).
77. Ahn, C. W. et al. Effects of growth hormone on insulin resistance and atherosclerotic risk factors in obese type 2 diabetic patients with poor glycaemic control. Clin. Endocrinol. (Oxf.) 64, 444-449 (2006).
78. Deepak, D. et al. Growth hormone and changes in energy balance in growth hormone deficient adults. Eur. J. Clin. Invest. 38, 622-627 (2008).
79. Hernberg-Ståhl, E. et al. Healthcare consumption decreases in parallel with improvements in quality of life during GH replacement in hypopituitary adults with GH deficiency. J. Clin. Endocrinol. Metab. 86, 5277-5281 (2001).
80. Snel, Y. E., Brummer, R. J., Doerga, M. E., Zelissen, P. M. & Koppeschaar, H. P. Energy and macronutrient intake in growth hormone-deficient adults: the effect of growth hormone replacement. Eur. J. Clin. Nutr. 49, 492-500 (1995).
81. Snyder, D. K., Underwood, L. E. & Clemmons, D. R. Persistent lipolytic effect of exogenous growth hormone during caloric restriction. Am. J. Med. 98, 129-134 (1995).
82. Albert, S. G. & Mooradian, A. D. Low-dose recombinant human growth hormone as adjuvant therapy to lifestyle modifications in the management of obesity. J. Clin. Endocrinol. Metab. 89, 695-701 (2004).
83. Richelsen, B. et al. Regulation of lipoprotein lipase and hormone-sensitive lipase activity and gene expression in adipose and muscle tissue by growth hormone treatment during weight loss in obese patients. Metabolism 49, 906-911 (2000).
84. Makimura, H. et al. Metabolic effects of a growth hormone-releasing factor in obese subjects with reduced growth hormone secretion: a randomized controlled trial. J. Clin. Endocrinol. Metab. 97, 4769-4779 (2012).
85. Attallah, H., Friedlander, A. L., Nino-Murcia, M. & Hoffman, A. R. Effects of growth hormone and pioglitazone in viscerally obese adults with impaired glucose tolerance: a factorial clinical trial. PLoS Clin. Trials 2, e21 (2007).
86. Svensson, J. et al. Treatment of obese subjects with the oral growth hormone secretagogue MK-677 affects serum concentrations of several lipoproteins but not lipoprotein(a). J. Clin. Endocrinol. Metab. 84, 2028-2033 (1999).
87. Bredella, M. A. et al. Effects of GH in women with abdominal adiposity: a 6-month randomized, double-blind, placebo-controlled trial. Eur. J. Endocrinol. 166, 601-611 (2012).
88. Mekala, K. C. & Tritos, N. A. Effects of recombinant human growth hormone therapy in obesity in adults: a meta analysis. J. Clin. Endocrinol. Metab. 94, 130-137 (2009).
89. Herrmann, B. L. et al. Effects of a combination of recombinant human growth hormone with metformin on glucose metabolism and body composition in patients with metabolic syndrome. Horm. Metab. Res. 36, 54-61 (2004).
90. Krusenstjerna-Hafstrøm, T. et al. Growth hormone (GH)-induced insulin resistance is rapidly reversible: an experimental study in GH-deficient adults. J. Clin. Endocrinol. Metab. 96, 2548-2557 (2011).
91. Svensson, J. et al. Two-month treatment of obese subjects with the oral growth hormone (GH) secretagogue MK-677 increases GH secretion, fat-free mass, and energy expenditure. J. Clin. Endocrinol. Metab. 83, 362-369 (1998).
92. Falutz, J. et al. Metabolic effects of a growth hormone-releasing factor in patients with HIV. N. Engl. J. Med. 357, 2359-2370 (2007).
93. Palmer, A. J. et al. Age-related changes in body composition of bovine growth hormone transgenic mice. Endocrinology 150, 1353-1360 (2009).
94. Ding, J., Berryman, D. E. & Kopchick, J. J. Plasma proteomic profiles of bovine growth hormone transgenic mice as they age. Transgenic Res. 20, 1305-1320 (2011).
95. Mathews, L. S., Hammer, R. E., Brinster, R. L. & Palmiter, R. D. Expression of insulin-like growth factor I in transgenic mice with elevated levels of growth hormone is correlated with growth. Endocrinology 123, 433-437 (1988).
96. Berryman, D. E., Christiansen, J. S., Johannsson, G., Thorner, M. O. & Kopchick, J. J. Role of the GH/IGF-1 axis in lifespan and healthspan: lessons from animal models. Growth Horm. IGF Res. 18, 455-471 (2008).
97. Berryman, D. E. et al. Effect of growth hormone on susceptibility to diet-induced obesity. Endocrinology 147, 2801-2808 (2006).
98. Kopchick, J. J., Bellush, L. L. & Coschigano, K. T. Transgenic models of growth hormone action. Annu. Rev. Nutr. 19, 437-461 (1999).
99. Berryman, D. E. et al. Comparing adiposity profiles in three mouse models with altered GH signaling. Growth Horm. IGF Res. 14, 309-318 (2004).
100. Bohlooly, Y. M. et al. Growth hormone overexpression in the central nervous system results in hyperphagia-induced obesity associated with insulin resistance and dyslipidemia. Diabetes 54, 51-62 (2005).
101. Wang, Z., Masternak, M. M., Al-Regaiey, K. A. & Bartke, A. Adipocytokines and the regulation of lipid metabolism in growth hormone transgenic and calorie-restricted mice. Endocrinology 148, 2845-2853 (2007).
102. Olsson, B. et al. Bovine growth hormone transgenic mice are resistant to diet-induced obesity but develop hyperphagia, dyslipidemia, and diabetes on a high-fat diet. Endocrinology 146, 920-930 (2005).
103. Bartke, A. Can growth hormone (GH) accelerate aging? Evidence from GH-transgenic mice. Neuroendocrinology 78, 210-216 (2003).
104. Gahete, M. D. et al. Elevated GH/IGF-I, due to somatotrope-specific loss of both IGF-I and insulin receptors, alters glucose homeostasis and insulin sensitivity in a diet-dependent manner. Endocrinology 152, 4825-4837 (2011).
105. List, E. O. et al. Endocrine parameters and phenotypes of the growth hormone receptor gene disrupted (GHR-/-) mouse. Endocr. Rev. 32, 356-386 (2011).
106. Zhou, Y. et al. A mammalian model for Laron syndrome produced by targeted disruption of the mouse growth hormone receptor/binding protein gene (the Laron mouse). Proc. Natl Acad. Sci. USA 94, 13215-13220 (1997).
107. Bartke, A. Impact of reduced insulin-like growth factor-1/insulin signaling on aging in mammals: novel findings. Aging Cell 7, 285-290 (2008).
108. Coschigano, K. T. et al. Deletion, but not antagonism, of the mouse growth hormone receptor results in severely decreased body weights, insulin, and insulin-like growth factor I levels and increased life span. Endocrinology 144, 3799-3810 (2003).
109. Berryman, D. E. et al. Two-year body composition analyses of long-lived GHR null mice. J. Gerontol. A. Biol. Sci. Med. Sci. 65, 31-40 (2010).
110. Egecioglu, E. et al. Growth hormone receptor deficiency results in blunted ghrelin feeding response, obesity, and hypolipidemia in mice. Am. J. Physiol. Endocrinol. Metab. 290, E317-E325 (2006).
111. Flint, D. J., Binart, N., Boumard, S., Kopchick, J. J. & Kelly, P. Developmental aspects of adipose tissue in GH receptor and prolactin receptor gene disrupted mice: site-specific effects upon proliferation, differentiation and hormone sensitivity. J. Endocrinol. 191, 101-111 (2006).
112. Bonkowski, M. S. et al. Long-lived growth hormone receptor knockout mice show a delay in age-related changes of body composition and bone characteristics. J. Gerontol. A. Biol. Sci. Med. Sci. 61, 562-567 (2006).
113. Li, Y., Knapp, J. R. & Kopchick, J. J. Enlargement of interscapular brown adipose tissue in growth hormone antagonist transgenic and in growth hormone receptor gene-disrupted dwarf mice. Exp. Biol. Med. (Maywood) 228, 207-215 (2003).
114. Liu, J. L. et al. Disruption of growth hormone receptor gene causes diminished pancreatic islet size and increased insulin sensitivity in mice. Am. J. Physiol. Endocrinol. Metab. 287, E405-E413 (2004).
115. Masternak, M. M. et al. Metabolic effects of intra-abdominal fat in GHRKO mice. Aging Cell 11, 73-81 (2012).
116. Lubbers, E. R. et al. Adiponectin in mice with altered growth hormone action: links to insulin sensitivity and longevity? J. Endocrinol. 216, 363-374 (2013).
117. Masternak, M. M. et al. Caloric restriction results in decreased expression of peroxisome proliferator-activated receptor superfamily in muscle of normal and long-lived growth hormone receptor/binding protein knockout mice. J. Gerontol. A. Biol. Sci. Med. Sci. 60, 1238-1245 (2005).
118. Longo, K. A. et al. Daily energy balance in growth hormone receptor/binding protein (GHR -/-) gene-disrupted mice is achieved through an increase in dark-phase energy efficiency. Growth Horm. IGF Res. 20, 73-79 (2010).
119. List, E. O. et al. The role of GH in adipose tissue: lessons from adipose-specific GH receptor gene-disrupted mice. Mol. Endocrinol. 27, 524-535 (2013).
120. Surwit, R. S., Kuhn, C. M., Cochrane, C., McCubbin, J. A. & Feinglos, M. N. Diet-induced type II diabetes in C57BL/6J mice. Diabetes 37, 1163-1167 (1988).
121. Surwit, R. S. et al. Differential effects of fat and sucrose on the development of obesity and diabetes in C57BL/6J and A/J mice. Metabolism 44, 645-651 (1995).
122. Huang, L. et al. The decline in pulsatile GH secretion throughout early adulthood in mice is exacerbated by dietary-induced weight gain. Endocrinology 153, 4380-4388 (2012).
123. List, E. O. et al. Growth hormone improves body composition, fasting blood glucose, glucose tolerance and liver triacylglycerol in a mouse model of diet-induced obesity and type 2 diabetes. Diabetologia 52, 1647-1655 (2009).
124. Nishimura M. Breeding of mouse strains for diabetes mellitus. Exp. Anim. 18, 147-157 (1969).
125. Hioki, C. et al. Effects of growth hormone (GH) on mRNA levels of uncoupling proteins 1, 2, and 3 in brown and white adipose tissues and skeletal muscle in obese mice. Horm. Metab. Res. 36, 607-613 (2004).
126. Sjögren, K. et al. Liver-derived insulin-like growth factor I (IGF-I) is the principal source of IGF-I in blood but is not required for postnatal body growth in mice. Proc. Natl Acad. Sci. USA 96, 7088-7092 (1999).
127. Casanueva, F. F. et al. Free fatty acids block growth hormone (GH) releasing hormone-stimulated GH secretion in man directly at the pituitary. J. Clin. Endocrinol. Metab. 65, 634-642 (1987).
128. Vijayakumar, A., Yakar, S. & Leroith, D. The intricate role of growth hormone in metabolism. Front. Endocrinol. (Lausanne) 2, 32 (2011).
129. Nielsen, S., Møller, N., Christiansen, J. S. & Jørgensen, J. O. Pharmacological antilipolysis restores insulin sensitivity during growth hormone exposure. Diabetes 50, 2301-2308 (2001).
130. Barclay, J. L. et al. GH-dependent STAT5 signaling plays an important role in hepatic lipid metabolism. Endocrinology 152, 181-192 (2011).
131. Nishizawa, H. et al. Nonalcoholic fatty liver disease in adult hypopituitary patients with GH deficiency and the impact of GH replacement therapy. Eur. J. Endocrinol. 167, 67-74 (2012).
132. Leung, K. C., Doyle, N., Ballesteros, M., Waters, M. J. & Ho, K. K. Insulin regulation of human hepatic growth hormone receptors: divergent effects on biosynthesis and surface translocation. J. Clin. Endocrinol. Metab. 85, 4712-4720 (2000).
133. Schulz, T. J. et al. Identification of inducible brown adipocyte progenitors residing in skeletal muscle and white fat. Proc. Natl Acad. Sci. USA 108, 143-148 (2011).
134. Divoux, A. et al. Fibrosis in human adipose tissue: composition, distribution, and link with lipid metabolism and fat mass loss. Diabetes 59, 2817-2825 (2010).
135. Kelder, B. et al. CIDE-A gene expression is decreased in white adipose tissue of growth hormone receptor/binding protein gene disrupted mice and with high-fat feeding of normal mice. Growth Horm. IGF Res. 17, 346-351 (2007).
136. Skaggs, S. R. & Crist, D. M. Exogenous human growth hormone reduces body fat in obese women. Horm. Res. 35, 19-24 (1991).
137. Drent, M. L., Wever, L. D., Ader, H. J. & van der Veen, E. A. Growth hormone administration in addition to a very low calorie diet and an exercise program in obese subjects. Eur. J. Endocrinol. 132, 565-572 (1995).
138. Luque, R. M. et al. Metabolic impact of adult-onset, isolated, growth hormone deficiency (AOiGHD) due to destruction of pituitary somatotropes. PLoS ONE 6, e15767 (2011).
139. Chen, W. Y., Wight, D. C., Mehta, B. V., Wagner, T. E. & Kopchick, J. J. Glycine 119 of bovine growth hormone is critical for growth-promoting activity. Mol. Endocrinol. 5, 1845-1852 (1991).
140. Andersen, B. et al. The Ames dwarf gene is required for Pit-1 gene activation. Dev. Biol. 172, 495-503 (1995).
141. Wang, Z., Al-Regaiey, K. A., Masternak, M. M. & Bartke, A. Adipocytokines and lipid levels in Ames dwarf and calorie-restricted mice. J. Gerontol. A. Biol. Sci. Med. Sci. 61, 323-331 (2006).
142. Heiman, M. L., Tinsley, F. C., Mattison, J. A., Hauck, S. & Bartke, A. Body composition of prolactin-, growth hormone, and thyrotropin-deficient Ames dwarf mice. Endocrine 20, 149-154 (2003).
143. Li, S. et al. Dwarf locus mutants lacking three pituitary cell types result from mutations in the POU-domain gene pit-1. Nature 347, 528-533 (1990).
144. Flurkey, K., Papaconstantinou, J., Miller, R. A. & Harrison, D. E. Lifespan extension and delayed immune and collagen aging in mutant mice with defects in growth hormone production. Proc. Natl Acad. Sci. USA 98, 6736-6741 (2001).
145. Donahue, L. R. & Beamer, W. G. Growth hormone deficiency in 'little' mice results in aberrant body composition, reduced insulin-like growth factor-I and insulin-like growth factor-binding protein-3 (IGFBP-3), but does not affect IGFBP-2, -1 or -4. J. Endocrinol. 136, 91-104 (1993).
146. Holzenberger, M. et al. IGF-1 receptor regulates lifespan and resistance to oxidative stress in mice. Nature 421, 182-187 (2003).